Targeting Adenosine A2A Receptor as a Novel Regenerative Therapy in Improving Chemobrain
Research Grant Recipient: Mi-Hyeon Jang, PhD
Award Value: $249,998
Research Focus: Cognitive dysfunction from chemotherapy
From the Investigator:
In the United States, cognitive dysfunction stemming from chemotherapy (chemobrain) is a major adverse condition affecting approximately 14 million cancer survivors with no known cure. Therefore, in this application, we aim to determine whether targeting the adenosine A2A receptor (Adora2a) is an effective regenerative strategy in promoting dendrite spine regeneration and improving chemotherapy-induced chemobrain. This understanding will provide insight into development of novel therapeutic interventions that prevent chemotherapy-induced cognitive dysfunction, thus resulting in a better quality of life for cancer survivors.